Merck Serono Announces Final Restructuring Plan - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck Serono Announces Final Restructuring Plan


ePT--the Electronic Newsletter of Pharmaceutical Technology

Merck Serono has revealed its “final efficiency program” for operations in Switzerland, which includes confirmation of the closure of sites in Geneva and Coinsins and their associated job cuts.

The restructuring was first announced in February 2012, but in April, in accordance with Swiss law, Swiss-based employees were given the opportunity to provide alternative proposals to avoid the job cuts, to reduce their number or to minimize their impact. The majority of proposals received from employees focused on maintaining all or some of the company’s activities in Geneva, developing a biotechnology cluster in Geneva or were measures relating to the company’s social plan. Several aspects of the received proposals relating to the social plan have been incorporated into the final program, including lowering the minimum age for early retirement from 58 to 56 years of age. In addition, employees who resign before the expected end of their contract will retain the right to part of their severance payment, under certain conditions.

However, Merck explained that it could not retain proposals advocating the maintenance of its activities in Geneva given the need to eliminate existing job-function duplications.

"The restructuring of Merck Serono's activities in Switzerland is part of an extensive program concerning all regions and all businesses of the Merck Group, necessitated by the unprecedented market shifts and the competitive environment facing the Group," Stefan Oschmann, Executive Board Member of Merck and CEO of Merck Serono, said in a press statement. "This restructuring process involves tough measures, but these are essential to safeguard the future of Merck Serono.”

As part of the final efficiency program, the company is also offering to facilitate the creation of start ups from employees using a fund of EUR 30 million ($38 million). Employees who proposed ideas for developing service companies targeting the biopharmaceutical industry are being encouraged to apply for start-up support, which may include capital investment, granting of intellectual property licenses and/or cessation of material assets. Employees can continue to submit project for consideration until 30 September 2012. Several proposals are already at advanced stages of discussion.

The majority of job transfers and cuts as part of the restructuring are expected to be completed by the second half of this year. Closure of the Geneva site is planned for mid-2013 and for 2014 for the Coinsins site.

The restructuring plan includes consolidating all headquarter functions on a Merck Serono campus in Darmstadt, Germany. Out of the 1250 positions currently located in Geneva, roughly 750 will be transferred to other sites and 500 will be eliminated. Approximately 80 positions in the Canton of Vaud will be made redundant while manufacturing operations based in Coinsins will be relocated to Aubonne.

Related Articles

Merck KGaA Announces Job Cuts

Merck KGaA Announces Restructuring

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here